Intellia Advances Gene Editing Programs Toward Hereditary Angioedema Commercial Reality [Yahoo! Finance]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: Yahoo! Finance
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Intellia Therapeutics (NasdaqGM:NTLA) has completed enrollment in its phase 3 HAELO trial of lonvo-z for hereditary angioedema. The FDA has lifted the clinical hold on Intellia's MAGNITUDE-2 trial for ATTR amyloidosis, clearing the way for enrollment to resume. The company is progressing commercialization plans in the U.S. for lonvo-z as a potential one-time gene-editing treatment for hereditary angioedema. Intellia Therapeutics, a gene editing company listed on NasdaqGM:NTLA, is moving its lead programs deeper into late-stage clinical territory. With lonvo-z now in a fully enrolled phase 3 study for hereditary angioedema and MAGNITUDE-2 allowed to restart for ATTR amyloidosis, the company is increasing its focus on translating CRISPR-based science into real-world treatment options. For investors, the combination of phase 3 progress and
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia Therapeutics: Why The Clinical Hold Lift Isn't A Total Victory [Seeking Alpha]Seeking Alpha
- This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy? [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound [Yahoo! Finance]Yahoo! Finance
NTLA
Earnings
- 2/26/26 - Beat
NTLA
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- NTLA's page on the SEC website